U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07114666) titled 'XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer' on Aug. 03.
Brief Summary: This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) in combination with chemotherapy as Adjuvant Therapy in pancreatic cancer patients following surgical resection.
Study Start Date: Aug. 18
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
BIOLOGICAL: XH001
mRNA neoantigen cancer vaccine
DRUG: Chemotherapy
Gemcitabine+Capecitabine or Oxaliplatin+lrinotecan+Calcium folinate+5-FU...